NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.29 -0.04 (-0.92 %)
(As of 03/26/2019 01:07 AM ET)
Previous Close$4.33
Today's Range$4.25 - $4.41
52-Week Range$3.62 - $9.42
Volume973,267 shs
Average Volume1.21 million shs
Market Capitalization$362.69 million
P/E Ratio-6.81
Dividend YieldN/A
Beta2.45
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.62 million
Book Value$1.20 per share

Profitability

Net Income$-67,660,000.00
Net Margins-433.09%

Miscellaneous

Employees64
Market Cap$362.69 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its earnings results on Thursday, March, 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.14. The biotechnology company had revenue of $3.24 million for the quarter, compared to analyst estimates of $10.99 million. Progenics Pharmaceuticals had a negative return on equity of 59.85% and a negative net margin of 433.09%. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 Wall Street analysts have issued twelve-month price objectives for Progenics Pharmaceuticals' stock. Their predictions range from $6.50 to $15.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $11.6250 in the next year. This suggests a possible upside of 171.0% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

What is the consensus analysts' recommendation for Progenics Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

Has Progenics Pharmaceuticals been receiving favorable news coverage?

Media headlines about PGNX stock have been trending somewhat negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Progenics Pharmaceuticals' key competitors?

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Novavax (NVAX), Dynavax Technologies (DVAX), Cara Therapeutics (CARA), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), Verastem (VSTM), Omeros (OMER) and Gilead Sciences (GILD).

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark R. Baker, CEO & Director (Age 64)
  • Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 51)
  • Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
  • Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
  • Melissa Downs, Sr. Mang. of Investor Relations

Who are Progenics Pharmaceuticals' major shareholders?

Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.00%), Eagle Asset Management Inc. (5.32%), Phocas Financial Corp. (2.01%), Pinnacle Associates Ltd. (1.71%), Royce & Associates LP (1.65%) and Bank of New York Mellon Corp (1.37%). View Institutional Ownership Trends for Progenics Pharmaceuticals.

Which institutional investors are selling Progenics Pharmaceuticals stock?

PGNX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Hikari Power Ltd, Pinnacle Associates Ltd., Bank of America Corp DE, Royce & Associates LP, Phocas Financial Corp., MetLife Investment Advisors LLC and Northern Trust Corp. View Insider Buying and Selling for Progenics Pharmaceuticals.

Which institutional investors are buying Progenics Pharmaceuticals stock?

PGNX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., Squarepoint Ops LLC, Oregon Public Employees Retirement Fund, Geode Capital Management LLC, Geode Capital Management LLC and Worth Venture Partners LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $4.29.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $362.69 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.

What is Progenics Pharmaceuticals' official website?

The official website for Progenics Pharmaceuticals is http://www.progenics.com.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]


MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  620
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel